Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Results From Solid Tumor Study Of LYMPHIR In Combination With Checkpoint Inhibitor
Portfolio Pulse from Benzinga Newsdesk
Citius Pharmaceuticals (NASDAQ:CTXR) announced positive results from a preclinical study on LYMPHIR, a combination therapy for solid tumors. The study showed that LYMPHIR, in combination with an anti-PD-1 checkpoint inhibitor, was more effective in treating solid tumors than either therapy alone. The results contributed to the design of two Phase 1 studies currently underway at the University of Pittsburgh and the University of Minnesota. The company believes the results highlight LYMPHIR's potential as a combination therapy, which could open up larger market opportunities.
October 31, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citius Pharmaceuticals' positive preclinical study results for LYMPHIR could potentially open up larger market opportunities. This could have a positive impact on the company's stock in the short term.
The positive results from the preclinical study of LYMPHIR, a combination therapy for solid tumors, could potentially open up larger market opportunities for Citius Pharmaceuticals. This could lead to increased revenues and profitability for the company, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100